thalidomide has been researched along with Carcinoma, Islet Cell in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Carcinoma, Islet Cell: A primary malignant neoplasm of the pancreatic ISLET CELLS. Usually it involves the non-INSULIN-producing cell types, the PANCREATIC ALPHA CELLS and the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS) in GLUCAGONOMA and SOMATOSTATINOMA, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors)." | 9.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| "Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors)." | 5.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kulke, MH | 1 |
| Stuart, K | 1 |
| Enzinger, PC | 1 |
| Ryan, DP | 1 |
| Clark, JW | 1 |
| Muzikansky, A | 1 |
| Vincitore, M | 1 |
| Michelini, A | 1 |
| Fuchs, CS | 1 |
1 trial available for thalidomide and Carcinoma, Islet Cell
| Article | Year |
|---|---|
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; An | 2006 |